Recruiting
Phase 1

Vinpocetine

Sponsor:

Stanford University

Code:

NCT06635746

Conditions

Fetal Alcohol Spectrum Disorders

Eligibility Criteria

Sex: All

Age: 18 - 40

Healthy Volunteers: Accepted

Interventions

Vinpocetine

Study Details

Brief summary:

The objective of this study is to determine whether vinpocetine is safe when taken at higher doses.

Conditions

Fetal Alcohol Spectrum Disorders

Study ID

NCT06635746

Start date

Oct 1, 2025

Status verified date

Nov, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 40

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Healthy adults 18-40 years old.
2. Proficient English.
3. Use of appropriate contraception if woman of childbearing potential.

Exclusion Criteria:

1. Major medical disease (e.g., epilepsy, diabetes, heart disease, active cancer, depression).
2. Those who score >18 overall on the BDI-II or >0 for item #9 (suicidal thoughts) at screening.
3. Use of centrally active medications.
4. History of allergy to vinpocetine.
5. IQ<80.
6. BMI≥30.
7. Pregnancy or lactation.

Study Design

Enrollment

16 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Vinpocetine

Participants will take increasing, single doses of vinpocetine to determine maximum tolerated dose (MTD) based on intolerable side effects. 10 healthy volunteers enrolled, consented and screened; 4 patients failed screening; 6 subjects have taken study drug as single ascending doses. At 350mg dose, 6 subjects tested - 1/6 with intolerable side effect (vomiting). At 400mg dose, 2 subjects had marked nausea. Maxium Tolerated Dose = 350mg single dose. Six subjects to be enrolled in the TID dosing study.

experimental: Pharmacokinetics for TID dosing.

After completion of single dose MTD study, 6 healthy volunteers will receive TID doses to determine PK of TID dosing using blood concentrations.

Interventions

Vinpocetine

Increasing doses of vinpocetine to assess tolerability.

Primary outcome measure

  • Treatment-Related Adverse Events to determine maximum tolerated single dose and associated concentrations of vinpocetine at different doses. [ Time Frame: Approximately weekly treatments across ~4-6 visits per participant from enrollment until 2 weeks post each treatment. ]

Central Contacts and Locations

Central contacts

Locations

Stanford University

Recruiting

Palo Alto, California, United States, 94304

Contacts

More Information

Sponsor

Stanford University

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • Cognition
  • Vinpocetine

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Stanford University on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.